연구용
제품 번호S7023
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| Molt-3 | Apoptosis Assay | 50μM | 2h | reduces melatonin-induced apoptosis | 23725013 | |
| Jurkat | Cell Viability Assay | 100-200μM | 24h | inhibits HaA4 induces apoptosis dependent of concentration | 23732481 | |
| T98G | Cell Viability Assay | 1-100μM | 24h | improves cell viability cotreatment with TS | 23769275 | |
| RKO | Cell Viability Assay | 10 μM | 24h | inhibits the decrease of cell viability caused by DAB | 23758064 | |
| Ec-109 | Apoptosis Assay | 10 μM | 48h | represses PE-mediated Ec-109 cell apoptosis | 23782641 | |
| HL-60 | Apoptosis Assay | 50µM | 4h | blocks the cleavage of caspase-3, -9, and PARP induced by 6s | 23804706 | |
| U251 | Apoptosis Assay | 20μM | 24h | inhibits casticin induced G2/M phase arrest and apoptosis | 23816816 | |
| HeLa | Apoptosis Assay | 20μM | 2h | inhibits DMMP induced apoptosis | 23863966 | |
| HL-60 | Apoptosis Assay | 100μM | 24h | inhibits apoptosis induced by abietane diterpenes | 23865778 | |
| K562 | Apoptosis Assay | 20μM | 48h | inhibits apoptosis induced by 4-MU | 23876826 | |
| THP-1 | Apoptosis Assay | 10-50μM | 2h | inhibits apoptosis induced by triptolide | 23900299 | |
| CAL27 | Apoptosis Assay | 10 μM | 2h | suppresses Cur-NPs-reduced viability by up to 90% | 23917396 | |
| COS-7 | Function Assay | 50µM | 24h | affects the processing of ATN1s with polyQ tracts | 23933208 | |
| Jurkat | Cell Viability Assay | 25-100μM | 6h | inhibits z-FA-CMK-induced cell death | 23933532 | |
| A431 | Kinase Assay | 40μM | 2h | blocks fisetin-induced cleavage of caspases and PARP | 23800058 | |
| RAW264.7 | Apoptosis Assay | 10 μM | 24h | decreases the apoptosis induced by GA | 23820203 | |
| Jurkat | Cell Viability Assay | 2μM | 4h | reverses growth inhibition and β-catenin decrease by HS-ASA | 23896061 | |
| L929 | Apoptosis Assay | 1.25–5 μM | 24h | augments TNFα-induced necroptosis and autophagy | 23941769 | |
| HL-60 | Apoptosis Assay | 50µM | 1h | DMSO | inhibits apoptosis induced by BA145 | 23948751 |
| CNE2 | Apoptosis Assay | 20μM | 48h | blocks LK-A-induced apoptosis | 23985029 | |
| CNE1 | Apoptosis Assay | 20μM | 48h | blocks LK-A-induced apoptosis | 23985029 | |
| IM-9 B | Apoptosis Assay | 20μM | 2h | DMSO | blocks anti-CD80 and anti-CD86 antibody-induced apoptosis | 24008628 |
| EBV-transformed B cells | Apoptosis Assay | 20μM | 2h | DMSO | blocks anti-CD80 and anti-CD86 antibody-induced apoptosis | 24008628 |
| MG-63 | Apoptosis Assay | 40μM | 24h | blocks the increased cleavage of caspase-3 and PARP induced by BBMD3 | 24025361 | |
| G292 | Apoptosis Assay | 40μM | 24h | blocks the increased cleavage of caspase-3 and PARP induced by BBMD3 | 24025361 | |
| KHOS | Apoptosis Assay | 40μM | 24h | blocks the increased cleavage of caspase-3 and PARP induced by BBMD3 | 24025361 | |
| Nalm-6 | Apoptosis Assay | 20μM | 4h | inhibits caspase-8 and caspase-3 activation and PARP-1 cleavage | 24039967 | |
| BGC-823 | Apoptosis Assay | 10 μM | 24h | reduces tetrandrine-induced apoptosis | 24098511 | |
| UM-SCC-10A | Apoptosis Assay | 50µM | 2h | reduces apoptosis induced by high-dose isoalantolactone | 24098753 | |
| A549 | Apoptosis Assay | 2.5μM | 24h | decreases oridonin-induced autophagy as well and Loss of Δψm also occurred during autophagic process | 24102522 | |
| RAW 264.7 | Apoptosis Assay | 20μM | 18h | increases LC3-II/β-actin ratio compared to ECTV-MOS treatment only | 24116707 | |
| SCCVII | Apoptosis Assay | 25μM | 1h | inhibits the cell killing after | 24126464 | |
| HeLa | Apoptosis Assay | 10/20μM | 24h | inhibits the activity of the majority of the members of the caspase-family | 24137266 | |
| SH-SY5Y | Apoptosis Assay | 10μM | 24h | attenuates caspase activation and cell death induced by HNE-2DG | 24145463 | |
| UD29a | Apoptosis Assay | 50μM | 24h | inhibits the cell death caused by NUT3 | 24190574 | |
| RPE | Apoptosis Assay | 100μM | 48h | partially inhibits the calpain-1 and -2 activation as well as the caspase activation | 24202052 | |
| OS | Apoptosis Assay | 20μM | 4h | inhibits the cell death caused by PDT | 24204937 | |
| 4T1 | Cell Viability Assay | 2.5-10μM | 4h | DMSO | rescues the cytotoxicity of 4T1 cells induced by SPDT in a concentration dependent manner | 24206161 |
| HEC-1B | Apoptosis Assay | 20μM | 1h | reduces TP-induced apoptosis caspase-3 and caspase-9 | 24213358 | |
| RKO-HIPK2i | Apoptosis Assay | 40μM | 6h | inhibits apoptosis induced by chemotherapy plus ZnCl2 | 24228232 | |
| U373 | Apoptosis Assay | 40μM | 6h | inhibits apoptosis induced by chemotherapy plus ZnCl2 | 24228232 | |
| ADF | Apoptosis Assay | 40μM | 6h | inhibits apoptosis induced by chemotherapy plus ZnCl2 | 24228232 | |
| MCC-2 | Apoptosis Assay | 20 μM | 6h | DMSO | blocks induced by staurosporine apoptosis cell death | 24262658 |
| A549 | Apoptosis Assay | 100μM | 48h | suppresses the apoptosis caused by piperine | 24272201 | |
| 5637 | Apoptosis Assay | 20μM | 1h | reverses CM-induced cell death | 24282433 | |
| MB49 | Apoptosis Assay | 20μM | 1h | reverses CM-induced cell death | 24282433 | |
| PDL fibroblasts | Kinase Assay | 80μM | 1h | inhibits Caspase-3 activity | 24314135 | |
| fetal rat lung fibroblasts | Kinase Assay | 80μM | 1h | inhibits Caspase-3 activity | 24314135 | |
| HepG2 | Apoptosis Assay | 10μM | 24h | reduces vimentin cleavage caused by LPS | 24325816 | |
| KB | Apoptosis Assay | 50μM | 24h | inhibits Lico-A-induced caspase-3 and PARP activation | 24337492 | |
| podocytes | Apoptosis Assay | 200μM | 6h | inhibits apoptosis induced by 3,4-DGE | 24337777 | |
| HaCaT | Apoptosis Assay | 100μM | 1h | blunts UVB-induced apoptosis in HaCaT cells | 24356997 | |
| k1735 | Apoptosis Assay | 20 μm | 4h | inhibits Salmonella-induced apoptosis | 24451116 | |
| SGC-7901 | Apoptosis Assay | 10μM | 24h | promotes the CGII-inhibited cell growth in SGC-7901 cells | 24454488 | |
| CLL | Apoptosis Assay | 25μM | 1h | partially blocks MLN2238-induced cell apoptosis | 24467634 | |
| Caki-1 | Apoptosis Assay | 20μM | 1h | inhibits SCP-induced apoptosis | 24504681 | |
| MIA-PaCa-2 | Apoptosis Assay | 24h | blocks cleavage of caspase-3 induced by both A-443654 and paclitaxel | 24510992 | ||
| A549 | Apoptosis Assay | 5μM | 24h | suppresses 6e (BK10040)-induced apoptosis | 24529871 | |
| HT-29 | Apoptosis Assay | 50μM | 48h | blocks the apoptosis induced by kaempferol | 24549175 | |
| BV-2 | Apoptosis Assay | 20μM | 2h | suppresses UV-induced chromatin extrusion and dilation of the nuclear envelope | 24558118 | |
| A549 | Apoptosis Assay | 50µM | 2h | DMSO | prevents the hypodiploid DNA content phase induced by cephalochromin | 24588135 |
| HDPC | Apoptosis Assay | 50µM | 24h | inhibits NO-induced apoptosis | 24634593 | |
| A375 | Apoptosis Assay | 20μM | 24h | reverses dicitrinone B-induced apoptosis | 24699111 | |
| L02 | Apoptosis Assay | 20μM | 1h | prevents the cell apoptosis induced by MEHP | 24706461 | |
| HCT116 | Apoptosis Assay | 20μM | 24h | inhibits the cell apoptotic induced by YLT205 | 24713812 | |
| IEC-6 | Apoptosis Assay | 10μM | 24h | prevents TcdA-induced caspase-3 cleavage and β-catenin degradation | 24711571 | |
| HeLa | Apoptosis Assay | 100μM | 24h | suppresses rate of cell death induced by overexpression of G59S or G71R p150glued | 24722468 | |
| HeLa | Apoptosis Assay | 50μM | 72h | DMSO | prevents apoptosis induced by compounds 1–5 | 24754786 |
| T cell | Cell proliferation assay | 0-100μM | 72h | IC50=70 μM, inhibits anti-CD3-induced T cell proliferation in PBMCs | 24768707 | |
| U937 | necroptosis Assay | 10 μM | 30 min | induces necroptosis combine with TNF | 24773756 | |
| LCC9 | Cell Viability Assay | 100μM | 5d | blocks cell death induced by combination L17 and | 24785256 | |
| AGS | Apoptosis Assay | 20μM | 12h | DMSO | reduces the induction of apoptosis in response to the EtOAc fraction in a dose-dependent manner | 24789703 |
| macrophage | Cell Viability Assay | 0-200μM | 24h | induces TNF- and Rip3-dependent necroptosis in macrophage | 24799565 | |
| Caco-2 | Apoptosis Assay | 40 μM | 4h | prevents ST-7-induced ZO-1 changes and TER drop | 24822183 | |
| SNU449 | Apoptosis Assay | 20μM | 48h | DMSO | decreases miR-451-induced apoptotic | 24841638 |
| LOVO | Apoptosis Assay | 10 µM | 1h | DMSO | restrains cell apoptosis induced by plus | 24874286 |
| SW1116 | Apoptosis Assay | 10 µM | 1h | DMSO | restrains cell apoptosis induced by plus | 24874286 |
| HCT116 | Apoptosis Assay | 20μM | 24h | abrogates of TQ-induced apoptosi | 24890449 | |
| P815 | Apoptosis Assay | 100 µM | 12h | DMSO | inhibits virus-induced apoptosis | 24923273 |
| THP-1 | Apoptosis Assay | 10μM | 1h | reduces apoptosis induced by ALA-SDT | 24923653 | |
| HeLa | Apoptosis Assay | 40μM | 24h | inhibits the increased apoptosis induced by siRNF121 | 24928685 | |
| AGS | Apoptosis Assay | 50μM | 24h | abolishs β-lapachone-induced cell death and inhibited growth | 25009698 | |
| C6 | Apoptosis Assay | 50μM | 48h | prevents the loss of cell viability caused by pregnenolone | 25013479 | |
| MM.1S | Apoptosis Assay | 100μM | 1h | efficiently prevents sorafenib-induced cell death combine with necrostatin-1 | 25037851 | |
| H929 | Apoptosis Assay | 100μM | 1h | partially blocks cell death caused by necrostatin-1 | 25037851 | |
| U266 | Apoptosis Assay | 100μM | 1h | partially blocks cell death caused by necrostatin-1 | 25037851 | |
| RPMI 8226 | Apoptosis Assay | 100μM | 1h | almost completely blocks cell death caused by necrostatin-1 | 25037851 | |
| IMR-32 | Apoptosis Assay | 40 μM | 2h | decrease in apoptotic cells compared to T-2 toxin | 25084755 | |
| K562 | Apoptosis Assay | 0.1-1μM | 1h | inhibits cleavage of HSP90 in a dose-dependent manner | 25119188 | |
| Jurkat | Apoptosis Assay | 20μM | 24h | DMSO | partially inhibit cell death of Jurkat cells induced by 10058-F4 combined with VPA | 25120723 |
| Ebs | Apoptosis Assay | 10-100μM | 24h | MMTS generation rate decreased as the concentration of z-VAD.fmk increased | 25134817 | |
| EA.hy926 | Apoptosis Assay | 10μM | 2h | inhibits apoptosis and facilitates autophagy in DENV2-infected EA.hy926 | 25138703 | |
| HUVECs | Apoptosis Assay | 10μM | 2h | inhibits apoptosis and facilitates autophagy in DENV2-infected HUVECs | 25138703 | |
| OS | Apoptosis Assay | 20/40μM | 72h | inhibits OS cell viability reduction by C6 ceramide | 25152399 | |
| MCF-7 | Apoptosis Assay | 20μM | 2h | decreases KDR-siRNA-induced apoptosis | 25182240 | |
| A549 | Apoptosis Assay | 10μM | 3h | reduces cell apoptosis caused by PQQ | 25161699 | |
| L929 | Apoptosis Assay | 10μM | 6h | induces necroptosis with TNF | 25195660 | |
| K562 | Apoptosis Assay | 50μM | 4h | inhibits Jac-A-induced cell apoptosis | 25241619 | |
| H9c2 | Apoptosis Assay | 50μM | 1h | inhibits DOX-induced caspase 3 activation but not the loss of cells | 25283819 | |
| 769-P | Apoptosis Assay | 40μM | 48h | reduces the number of Annexin V-positive cells | 25279191 | |
| Caki-1 | Apoptosis Assay | 40μM | 48h | reduces the number of Annexin V-positive cells | 25279191 | |
| NBL-W-S | Apoptosis Assay | 50μM | 1h | fully rescues cell viability after GANT-61 treatment | 25323222 | |
| A549 | Apoptosis Assay | 2.5-25μM | 1h | decreases the population of apoptotic cells depend on concentrations | 25342427 | |
| A549 | Apoptosis Assay | 50μM | 24h | reverses ribosome biogenesis and apoptosis caused by Chijongdan | 25349781 | |
| A375 | Apoptosis Assay | 30μM | 2h | prevents the drug-induced PARP cleavage | 25376115 | |
| COS7 | Apoptosis Assay | 10μM | 48h | partially prevented FC101-induced cell death | 25384025 | |
| COS7 | Kinase Assay | 10μM | 24h | increases caspase 3/7 activities | 25384025 | |
| Cytotoxicity Assay | Cell Viability Assay | 20μM | 48h | prevent MHMD-induced cell death | 25392116 | |
| L929-N | Cytotoxicity Assay | 20 μM | 24h | enhances death via autocrine TNFα production | 25398540 | |
| L929-A | Cytotoxicity Assay | 20 μM | 24h | inhibits TNFα-induced cell death | 25398540 | |
| Primary hepatocytes | Apoptosis Assay | 50μM | 18h | inhibits apoptosis of hepatocytes induced by Act D and TNF-α | 25407538 | |
| INS-1 | Apoptosis Assay | 50μM | 6h | DMSO | decreases the proportion of early apoptotic cells | 25430897 |
| A549 | Apoptosis Assay | 10μM | 24h | blocks DMAS-induced cleavage of caspase-3 and PARP and apoptotic cell death | 25434989 | |
| AGS | Apoptosis Assay | 10μM | 1h | prevents curcumin-induced cleavage of caspase-3, -8, and -9 proteins | 25492214 | |
| HL-60 | Cytotoxicity Assay | 100μM | 1h | DMSO | improves viability of TCNAs-treated cells | 25502932 |
| MKN28 | Apoptosis Assay | 10μM | 30min | DMSO | inhibits TNF-α plus CHX-induced apoptosis | 25513960 |
| MDA-MB-231 | Cytotoxicity Assay | 10μM | 1h | augments cell death after CHUA treatment | 25521501 | |
| DLD1 | Apoptosis Assay | 20 μM | 1h | partly reverses cell apoptosis caused by WSP1 | 25524246 | |
| MM | Apoptosis Assay | 50μM | 20min | partly inhibits SHK-induced cell death | 25530098 | |
| Primary human placental cytotrophoblasts | Apoptosis Assay | 30μM | 24h | DMSO | reverses the inhibition of 11β-HSD2 by triclosan | 25642592 |
| Neocortical Neuron | Neurotoxicity Assay | 100μM | 1h | antagonizes Hoiamide A-Induced Neurotoxicity | 25675001 | |
| U87 | Growth Inhibition Assay | 50μM | 1h | recovers cell growth from TMZ treatment | 25681668 | |
| A549 | Apoptosis Assay | 10 μM | 24h | DMSO | promotes HBC-treated A549 cell survival & attenuates the cleaved PARP expression | 25683568 |
| MCF-7 | Apoptosis Assay | 10μM | 2h | inhibits the cell death induced by 3B | 25722114 | |
| SGC-7901 | Apoptosis Assay | 20 μM | 1h | inhibits the cell death induced by oxaliplatin | 25767076 | |
| HeLa | Apoptosis Assay | 10μM | 48h | declines the rate of apoptosis dramatically | 25772545 | |
| A549 | Apoptosis Assay | 20 μM | 24h | reduces cell death caused by HFCP treatment | 25794149 | |
| GC1a | Apoptosis Assay | 50μM | 24h | indicates a protective effect against | 26169075 | |
| HGL5 | Apoptosis Assay | 50μM | 24h | indicates a protective effect against | 26169075 | |
| HepG2 | Apoptosis Assay | 20μM | 1h | attenuated the apoptotic induction of III-10 | 26164795 | |
| BEL-7402 | Apoptosis Assay | 20μM | 1h | attenuated the apoptotic induction of III-10 | 26164795 | |
| CEF | Kinase Assay | 0,33,67,100μM | 15min | down-regulates PR enzyme activity to 40% at 100μM | 26102339 | |
| SP2/0 | Apoptosis Assay | 100μM | 1h | DMSO | blocks the apoptosis of SP2/0 cells | 26074732 |
| HUVEC-2c | Apoptosis Assay | 50μM | 6h | decreased the ox-LDL-induced autophagy | 26021729 | |
| U1 | Apoptosis Assay | 0-100μM | 2h | reduces drug-induced apoptosis and subsequent HIV-1 replication in a dose-dependent manner | 25980942 | |
| ACH-2 | Apoptosis Assay | 0-200μM | 2h | reduces drug-induced apoptosis and subsequent HIV-1 replication in a dose-dependent manner | 25980942 | |
| U1 | Kinase Assay | 100μM | 2h | inhibits caspase-3 | 25980942 | |
| A549/V16 | Apoptosis Assay | 50μM | 1h | represses TG/TM-induced apoptosis | 25946033 | |
| SGN | Apoptosis Assay | 20mM | 48h | has no influence on AIF, calpain expression or cell apoptosis | 25874633 | |
| HCT116 | Apoptosis Assay | 50μM | 2h | inhibits the cell death induced by DDVP | 25868818 | |
| DTK-SME | Apoptosis Assay | 50μM | 2h | DMSO | partially inhibits the apoptosis induced by bupivacaine | 25843897 |
| HL-60 | Apoptosis Assay | 50μM | 48h | reduces cell death caused by SKI-II treatment | 25824043 | |
| U937 | Apoptosis Assay | 50μM | 48h | reduces cell death caused by SKI-II treatment | 25824043 | |
| hMSC12 | Apoptosis Assay | 100μM | 4d | inhibits osteogenic culture-induced cell death and calcification | 23657822 | |
| HM7 | Apoptosis Assay | 20μM | 1h | blocks apicularen A acetate-induced caspase-3 activation and PARP cleavage | 23583412 | |
| Hep-2 | Apoptosis Assay | 20μM | 24h | DMSO | alleviates the decrease of cell viability induced by silibinin | 23580032 |
| HSCs | Apoptosis Assay | 50μM | 24h | DMSO | inhibits nilotinib-induced DNA damage indicated by PARP cleavage | 23499874 |
| HL-60 | Cytotoxicity Assay | 20μM | 24h | reduces the cytotoxic effect of Ery5 | 23494480 | |
| HA | Apoptosis Assay | 50μM | 24h | suppresses the cleavage of PARP and caspase-3, -7, and -9 induced by | 23475956 | |
| C666-1 | Apoptosis Assay | 50μM | 24h | suppresses the cleavage of PARP and caspase-3, -7, and -9 induced by | 23475956 | |
| Hepa1-6 | Apoptosis Assay | 50μM | 2h | inhibits curcumin and resveratrol-induced apoptosis | 23446753 | |
| PLC/PRF/5c | Apoptosis Assay | 50μM | 1h | prevents apoptosis triggered by CIN | 23438824 | |
| HCT116 | Apoptosis Assay | 100μM | 1.5h | inhibits Os-induced cell death | 23744353 | |
| HCEC | Function Assay | 50μM | 72h | DMSO | restores of the normal HCEC phenotype | 23742011 |
| Primary rat cerebral cortical neurons | Apoptosis Assay | 100μM | 1h | prevents Cd-induced apoptosis and cell death | 23741317 | |
| MDA-MB-231 | Apoptosis Assay | 25μM | 24h | abrogates cytotoxicity and cleavage of caspase-3 and PARP induced by Rg3 | 25337544 | |
| NLRP3-Tet-on-MC/9 | Apoptosis Assay | 10-40μM | 12h | attenuates the cell death caused by CAPS-associated NLRP3 mutants in the Tet-on system | 23703389 | |
| KNS42 | Apoptosis Assay | 50μM | 1h | reduces cell death and completely abolished caspase 3/7 activity in response to ABT-263/2DG/ combination | 23691145 | |
| MCF-7 | Apoptosis Assay | 20μM | 72h | inhibits equol- and 4-OHT-mediated apoptosis | 23675643 | |
| hCMEC/D3 | Apoptosis Assay | 25μM | 72h | reduces LtxA induced apoptosis | 23665198 | |
| Jurkat | Apoptosis Assay | 12.5-50μM | 1h | dose dependently suppresses SPH-induced Par-4 cleavage, PARP cleavage, DNA fragmentation, and loss of viability | 23442976 | |
| CNE-1 | Apoptosis Assay | 20μM | 24h | inhibits RAD001-induced cell death | 23426850 | |
| HONE-1 | Apoptosis Assay | 20μM | 24h | inhibits RAD001-induced cell death | 23426850 | |
| astrocytes cell | Apoptosis Assay | 40μM | 6h | reduces early apoptosis induced by staurosporine | 23411778 | |
| U-937 | Apoptosis Assay | 10μM | 30min | prevents TNF-induced necroptosis | 23410748 | |
| MDA-MB-231 | Apoptosis Assay | 100μM | 1h | inhibits sensitization to TRAIL upon MTDH down-regulation | 23408429 | |
| HeLa | Apoptosis Assay | 100μM | 2h | blocks JRS-15 Induces Apoptotic Cell Death | 23344045 | |
| Ec109 | Apoptosis Assay | 10μM | 6h | blocks apoptotic combination of Tat-SmacN7 and radiation | 23338568 | |
| H460 | Apoptosis Assay | 10μM | 6h | blocks apoptotic combination of Tat-SmacN7 and radiation | 23338568 | |
| HeLa | Apoptosis Assay | 50μM | 1.5h | abrogates Chlamydia-induced apoptosis | 23303804 | |
| SK-HEP1 | Apoptosis Assay | 100μM | 1h | inhibits CrT1 activated caspase-3, -7, -8, -9, and poly(ADP-ribose) polymerase | 23302650 | |
| QGY7701 | Apoptosis Assay | 25μM | 1.5h | inhibits accumulation of sub-G1 phase induced by DOX + quercetin | 23240061 | |
| HepG2 | Apoptosis Assay | 20μM | 30min | inhibits the enhanced cell death by combined treatment of apigenin and TRAIL | 23224239 | |
| U87 | Apoptosis Assay | 25μM | 2h | decreases isoliquiritigenin (ISL)-induced apoptotic cell death, but not necrotic cell death | 23229626 | |
| HSC-2 | Apoptosis Assay | 25/50μM | 1h | inhibits SN-38-induced cytotoxicity | 23155248 | |
| HSC-4 | Apoptosis Assay | 25/50μM | 1h | inhibits SN-38-induced cytotoxicity | 23155248 | |
| CL-1 | Apoptosis Assay | 20μM | 1h | blocks OP449 induced cell death | 23131782 | |
| MEL | Apoptosis Assay | 20μM | 24h | DMSO | impaires P2X7-induced MEL cell apoptosis | 23014887 |
| Bel-7402 | Caspase Activation Assay | 50μM | 2h | inhibits PCE-induced anoikis | 23008742 | |
| Eca-109 | Apoptosis Assay | 25μM | 30min | inhibits BJ-B11-induced cell death | 23076967 | |
| MEL | Apoptosis Assay | 20μM | 1h | DMSO | impaires P2X7-induced MEL cell apoptosis | 23014887 |
| Bel-7402 | Apoptosis Assay | 50μM | 2h | inhibits PCE-induced anoikis | 23008742 | |
| L929 | Function Assay | 2.5μM | 1h | increases RIP1 expression and exacerbated TNFα-induced mitochondrial dysfunction and ROS production | 23000518 | |
| RCC | Cell Viability Assay | 100μM | 24h | recoveres the viability of cells exposed to 15d-PGJ2 | 22991494 | |
| NB2a/d1 | Apoptosis Assay | 100μM | 72h | attenuates staurosporine-induced caspase activity, PARP, and tau cleavage | 22988541 | |
| T cell | Growth Inhibition Assay | 25-100μM | 24h | dose-dependently inhibited T cell proliferation mediated through the co-stimulation with anti-CD3 and anti-CD28 | 22982538 | |
| K562 | Apoptosis Assay | 100μM | 1h | blocks Abnobaviscum F-induced apoptosis | 22972372 | |
| Jurkat | Apoptosis Assay | 40μM | 1h | abolishes FasL-induced caspase activation and cell death | 22942738 | |
| BGC-823 | Apoptosis Assay | 100μM | 1h | partially rescues cells against damage of daidzein | 22926545 | |
| Hep3B | Apoptosis Assay | 50μM | 1h | blocks apoptosis induced by HEGCs | 22923154 | |
| LLC-PK1 | Apoptosis Assay | 20μM | 1h | prevents degradation of Atg5, beclin-1, and Atg12 proteins | 22896037 | |
| A549 | Apoptosis Assay | 50μM | 1h | blocks the BAI-induced apoptosis | 22887215 | |
| SGC-7901 | Apoptosis Assay | 10μM | 24h | inhibits β,β-dimethylacrylshikonin-induced apoptosis | 22848597 | |
| DM6 | Apoptosis Assay | 100μM | 72h | blocks both E2F-1 and E2Ftr-mediated cytotoxicity | 22825328 | |
| MCF-7, MDA-MB-468, Caco-2 | Growth Inhibition Assay | 50μM | 48h | inhibits the cell growth inhibition induced by saponin | 22800968 | |
| A2750 | Apoptosis Assay | 20μM | 2h | DMSO | blocks caspase cleavage during helenalin treatment and reduces autophagic cell death | 22784363 |
| U87 | Apoptosis Assay | 20μM | 24h | reduces the apoptosis rate induced by PLAB | 22778780 | |
| HT1080 | Growth Inhibition Assay | 50μM | 7d | inhibits the cell growth inhibition caused by combined treatment of DCA and OMP | 22740984 | |
| A549 | Apoptosis Assay | 50μM | 2h | partially decreases sodium selenite-induced apoptosis | 22721804 | |
| Primary OPC | Apoptosis Assay | 1μM | 6h/24h | reduces the percentage of cells in early- and late-apoptosis/necrosis | 22707385 | |
| PMNs | Apoptosis Assay | 40μM | 6h | DMSO | reversed the amount of cleaved caspase-3 to near vehicle levels | 22692577 |
| A549 | Apoptosis Assay | 50μM | 1h | prevents apoptosis induced by Baohuoside I | 22687635 | |
| AGS | Apoptosis Assay | 20μM | 12h | inhibits the activation of pro-caspase-3 in response to the EtOAc fraction | 22687398 | |
| shC9 | Apoptosis Assay | 10μM | 16h | blunts SHH expression in shC9 cells exposed to either PA or LPC | 22641094 | |
| primary MEFs | Function Assay | 12h | increases mitochondrial membrane depolarization | 22613767 | ||
| 3T9 MEFs | Function Assay | 16h | increases cytochrome c release after | 22613767 | ||
| 3T9 MEFs | Function Assay | 18h | upregulates initiator caspase-9 but downregulates effector caspases after treatment | 22613767 | ||
| MDA-MB-231 | Apoptosis Assay | 20μM | 4d | reduces the cell apoptosis induced by treatment was significantly | 22593441 | |
| C6 | Apoptosis Assay | 10μM | 24h | blocks the suppressive effect of the peptide on viability | 22588980 | |
| HL-60 | Apoptosis Assay | 100μM | 24h | inhibits the cell apoptosis selected (+)-menthyl β-(1→6)-diglucopyranoside 5 | 22546669 | |
| HL-60 | Apoptosis Assay | 10-80μM | 4h | inhibits TGHQ-induced cell apoptosis | 22523229 | |
| BCC | Apoptosis Assay | 50μM | 1h | inhibits DATS-mediated growth inhibition | 22519436 | |
| RAW 264.7 | Apoptosis Assay | 50/100μM | 1h | concentration-dependent inhibits DON-induced rRNA cleavage | 22491426 | |
| K562 | Apoptosis Assay | 25μM | 2h | prevents apoptosis induced by co-treatment with amurensin G and TRAIL | 22483777 | |
| SGC-7901 | Apoptosis Assay | 20 μM | 2h | attenuates H2O2 or TNF α-induced cell apoptosis as well as caspase-3 activity | 22471589 | |
| PC3 | Apoptosis Assay | 10μM | 4h | counters flavocoxid-induced caspase-related apoptosis | 22471974 | |
| SMMC-7721 | Apoptosis Assay | 50μM | 48h | attenuates oTR-induced apoptosis | 22465833 | |
| HeLa | Apoptosis Assay | 50 μM | 4/8h | inhibits STS-induced late-phase apoptotic events | 22460504 | |
| HeLa | Apoptosis Assay | 50 μM | 1h | suppresses the FRAP-induced accumulation of annexin V positive cells | 22449440 | |
| T47D | Apoptosis Assay | 100μM | 1h | blocks the generation of E-cad/CTF2 by STS | 22401168 | |
| HeLa | Apoptosis Assay | 30μM | 4h | increases the general cell viability 48 h after photodynamic treatment | 22394248 | |
| HCC | Apoptosis Assay | 20 μM | 2h | attenuates the DHA induced activation of PARP | 22342732 | |
| mESCs | Apoptosis Assay | 2.5μM | 2h | inhibits the NaF-mediated caspase activation | 22285274 | |
| EMT-6 | Cytotoxicity Assay | 100μM | 1h | partially blocked cell death induced by siramesine | 22251921 | |
| MCF7 | Apoptosis Assay | 50 μM | 1h | inhibits PA activated caspase-3, -9, and poly(ADP-ribose) polymerase | 22223345 | |
| K562 | Apoptosis Assay | 20 μM | 48h | DMSO | blocks inhibition of viability and apoptosis induction | 22216158 |
| Molt4-hyg | Apoptosis Assay | 10μM | 0.5h | blocks farnesol-induced caspase-3-like activity | 26275811 | |
| HeLa | Apoptosis Assay | 10μM | 0.5h | inhibits apoptosis induced by the combined treatment with gomisin N and TRAIL | 22179661 | |
| Jurkat T | Apoptosis Assay | 30μM | 0.5h | DMSO | blocks the ziram-induced apoptosis | 22159898 |
| Neutrophil | Apoptosis Assay | 20μM | 0.5h | attenuates the pro-apoptotic effect of MaR1 | 26196844 | |
| HCT116 | Apoptosis Assay | 50 μM | 2h | reverses synergistic apoptosis effects of and NPC-16 | 22159752 | |
| MDA-MB-231 | Apoptosis Assay | 2.5-7.5μM | 2h | inhibits the cell death of MDA-MB-231 cells induced by SDT in a concentration dependent manner | 22115526 | |
| LNCaP | Apoptosis Assay | 40μM | 2h | inhibits butein induced cell apoptosis | 22114764 | |
| MB231 | Apoptosis Assay | 100μM | 1h | DMSO | abrogates the induction of cell death by WEE1 inhibition, TRAIL treatment, and the combination | 22112940 |
| HCC38 | Apoptosis Assay | 100μM | 1h | DMSO | abrogates the induction of cell death by WEE1 inhibition, TRAIL treatment, and the combination | 22112940 |
| MDA-MB231 | Apoptosis Assay | 50 μM | 24h | DMSO | abrogates curcumin-induced cell death | 22101335 |
| LNCaP | Apoptosis Assay | 50 μM | 24h | DMSO | abrogates curcumin-induced cell death | 22101335 |
| HCT116 | Apoptosis Assay | 50 μM | 24h | DMSO | abrogates curcumin-induced cell death | 22101335 |
| Ishikawa | Apoptosis Assay | 25μM | 24h | reduces cell death and apoptosis induced by Baf A1 | 22088918 | |
| YD-8 | Apoptosis Assay | 100μM | 1h | inhibits PLEO-induced apoptosis | 22086183 | |
| eosinophil | Apoptosis Assay | 90μM | 24h | inhibits apoptosis induced by Fas antibody | 22079334 | |
| L929 | Growth Inhibition Assay | 2.5μM | 24h | inhibits the expression of p-p38 and NF-κB to augment TNFα-induced necroptosis and autophagy | 22027097 | |
| YD-8 | Apoptosis Assay | 100μM | 1h | blocks the GS-HCl-induced apoptosis | 22020078 | |
| HBx | Apoptosis Assay | 25μM | 48h | DMSO | reduced cell death induced by 3-MA | 22020078 |
| U937 | Apoptosis Assay | 50 μM | 1h | inhibits HF-induced apoptosis | 21998731 | |
| HL60 | Apoptosis Assay | 40μM | 40min | DMSO | blocks BNDC compounds induce exposure of phosphatidylserine and DNA fragmentation | 21983296 |
| M-14 | Apoptosis Assay | 25μM | 0.5h | inhibits both the crude extract- and compound-induced apoptosis | 21954959 | |
| SK-BR-3 | Apoptosis Assay | 50 μM | 2h | blocks apoptotic DNA fragmentation induced by combination of SM-164 and radiation | 21901386 | |
| MDA-MB-468 | Apoptosis Assay | 50 μM | 2h | blocks apoptotic DNA fragmentation induced by combination of SM-164 and radiation | 21901386 | |
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 467.49 | 화학식 | C22H30FN3O7 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 187389-52-2 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | Z-VAD(OMe)-FMK | Smiles | CC(C)C(C(=O)NC(C)C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)OCC1=CC=CC=C1 | ||
|
In vitro |
DMSO
: 93 mg/mL
(198.93 mM)
Ethanol : 2 mg/mL Water : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| 특징 |
A key compound for apoptosis studies.
|
|---|---|
| Targets/IC50/Ki |
Pan-caspase
(THP.1, Jurkat T-cells) |
| 시험관 내(In vitro) |
Z-VAD-FMK (10 μM)는 THP.1 세포에서 Apoptosis를 억제합니다. 이 화합물 (10 μM)은 대조군 THP.1 세포 용해물에서 PARP protease 활성화를 억제합니다. 그것은 (10 μM) 온전한 THP.1 및 Jurkat 세포에서 CPP32의 처리를 억제합니다. 이 화학물질 (50 μM) 동시 처리는 camptothecin으로 처리된 HL60 세포의 Apoptotic 형태를 제거합니다. 그것은 (50 μM) HL60 세포에서 camptothecin 유도 DNA fragmentation을 차단합니다. 이 화합물 (50 μM)은 S2 세포에서 dSMN dsRNA 유도 Apoptosis에 따른 세포 사멸을 억제합니다. 그것은 (50 μM) S2 세포에서 형질감염된 세포의 생존율을 26%에서 63%로 증가시킵니다. 이 억제제 (> 100 μM)는 TNFα 유도 호중구 Apoptosis를 강화하지만, 낮은 농도 (1-30 μM)는 인간 호중구에서 TNFα 자극 Apoptosis를 완전히 차단합니다. 그것은 (10 mM) 전방 기질 각막 세포에서 Apoptosis를 억제합니다. 이 화학물질 (10 mM)은 TUNEL 분석법으로 검출된 전방 기질 각막 세포에서 Apoptosis를 억제합니다. |
| 생체 내(In vivo) |
생체 내 Z-VAD-FMK 투여는 이전에 독성이 없으며 동물 모델에서 apoptosis를 예방하는 것으로 나타났습니다. 복강 내 HK-GBS 주사는 조기 분만을 유발하며, 이 화합물로 전처리하면 생쥐의 조기 분만을 지연시킵니다. OVA 감작 생쥐에서 이 화학 물질의 처리는 알레르기 유발성 백혈구 침윤을 억제합니다. OVA 공격 직전에 이 화합물을 전신 주사하면 OVA 감작/공격 생쥐에서 염증 세포 축적, 점액 과분비 및 Th2 사이토카인 방출이 감소했습니다. 이 화합물로 처리하면 렌즈 상피 세포와 각질 세포의 최종 분화, 단핵구의 대식세포 분화, 적혈구 전구체의 분화가 차단되었습니다. 이 화학 물질은 알레르기 유발성 기도 염증 및 과민 반응을 약화시켰습니다. 생체 내에서 이 화합물로 처리하면 생체 외에서 후속적인 T 세포 활성화도 예방되었습니다. |
참조 |
|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | IRF-1 / p-STAT1 / cleaved PARP1 / cleaved-caspase3 Beclin1 / Atg5 / Atg7 / LC-3I / LC-3II p23 / Hsp90 / hTRET / MMP2 cyto C |
|
27191889 |
| Growth inhibition assay | Cell viability |
|
12522090 |
| Immunofluorescence | cytochrome c Smac/DIABLO Endo G AIF |
|
11726499 |
| ELISA | IL-1β |
|
26254306 |
질문 1:
Can you suggest an in vivo formulation of it for animal studies?
답변:
For in vivo study of this compound, the IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).
질문 2:
What is the difference between S7023 & S8102?
답변:
Unlike S7023, it does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.